Human UGT1A6 pharmacogenetics
Authors:
- Jeffrey J ZalatorisJZJeffrey J Zalatoris
- Rebecca L BlanchardRBRebecca L Blanchard
- 1 August 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 14 (8) , 487-499
Abstract
Background UDP-glucuronosyltransferase (UGT) enzymes catalyze the glucuronidation and typically inactivation of endogenous and exogenous molecules including steroid hormones, bilirubin and many drugs. The UGT1A6 protein is expressed predominantly in liver and metabolizes small phenolic drugs including acetaminophen, salicylates and many β-blockers. Interindividual variation in the capacity of humans to glucuronidate drugs has been observed. Results We have identified a novel common single nucleotide polymorphism (SNP) in the human UGT1A6 gene resulting in a Ser7Ala change in encoded amino acid. We have further functionally characterized that polymorphism in the context of two previously reported polymorphisms, Thr181Ala and Arg184Ser. These non-synonymous cSNPs define four common haplotypes. Alleles appear with similar frequencies in Caucasian and African-American populations with distributions adhering to Hardy–Weinberg equilibrium. UGT1A6 genotype, rate of substrate glucuronidation and level of immunoreactive UGT1A6 protein was determined. A 25-fold variation in the rate of substrate glucuronidation and an 85-fold variation in level of immunoreactive protein were measured. Liver tissue samples that were homozygous for UGT1A6*2 exhibited a high rate of glucuronidation relative to tissues with other genotypes. Biochemical kinetic studies of recombinant UGT1A6 expressed in HEK293 cells indicated that the UGT1A6*2 allozyme, expressed homozygously, had almost two-fold greater activity toward p-nitrophenol than UGT1A6*1 and when expressed heterozygously (UGT1A6*1/*2) it was associated with low enzyme activity. Conclusions These data suggest that common genetic variation in human UGT1A6 confers functionally significant differences in biochemical phenotype as assessed in human tissue and cultured cells expressing recombinant allozymes. This genetic variation might impact clinical efficacy or toxicity of drugs metabolized by UGT1A6.Keywords
This publication has 34 references indexed in Scilit:
- Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locusPharmacogenetics, 2001
- Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significancePharmacogenetics, 2000
- Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 genePharmacogenetics, 2000
- Human UDP-Glucuronosyltransferases: Metabolism, Expression, and DiseaseAnnual Review of Pharmacology and Toxicology, 2000
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- STRUCTURAL AND FUNCTIONAL STUDIES OF UDP-GLUCURONOSYLTRANSFERASES*Drug Metabolism Reviews, 1999
- Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implicationsPharmacogenetics, 1997
- The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergencePharmacogenetics, 1997
- Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndromeThe Lancet, 1996
- Gene Structure at the Human UGT1 Locus Creates Diversity in Isozyme Structure, Substrate Specificity, and RegulationProgress in Nucleic Acid Research and Molecular Biology, 1995